Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
gp100 Reactive PBL and Aldesleukin in Metastatic Melanoma
NCT00665470Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Apr 2008
- Primary completion
- Apr 2012
- Modality
- Gene Editing, Gene Silencing, Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of gp100:154-162 reactive peripheral blood lymphocytes in melanoma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Clinical Tumor Regression (Objective Response) at 30 months and Toxicity as Assessed by CTCAE V3.0 at 16 months. Started Apr 2008; status: completed.
02
Drugs
gp100:154-162 reactive peripheral blood lymphocytes
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00665470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00665470.